Category Archives: Gene Medicine

-Spinal cord injury (SCI) creates a complex microenvironment that is not conducive to repair; growth factors are in short supply, whereas factors that inhibit regeneration are plentiful. In a new report, researchers have developed a structural bridge material that simultaneously stimulates IL-10 and NT-3 expression using a single bi-cistronic vector to alter the microenvironment and enhance repair. The article is reported in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the article for free on the Tissue Engineering website through May 17, 2020.

In Polycistronic Delivery of IL-10 and NT-3 Promotes Oligodendrocyte Myelination and Functional Recovery in a Mouse Spinal Cord Injury Model, Lonnie D. Shea, PhD, University of Michigan, and coauthors report the development of a new poly(lactide-co-glycolide) (PLG) bridge with an incorporated polycistronic IL-3/NT-3 lentiviral construct. This material was used to stimulate repair in a mouse SCI model. IL-10 was included to successfully stimulate a regenerative phenotype in recruited macrophages, while NT-3 was used to promote axonal survival and elongation. The combined expression was successful; axonal density and myelination were increased, and locomotor functional recovery in mice was improved.

Inflammation plays a vital role in tissue repair and regeneration, and the use of a PLG bridge to take advantage of the inflammatory response to promote SCI repair is an elegant way to take advantage of these natural processes to improve SCI healing, says Tissue Engineering Co-Editor-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX.

About the Journal

Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and John P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Leadership of Tissue Engineering Parts B (Reviews) and Part C (Methods) is provided by Katja Schenke-Layland, PhD, Eberhard Karls University, Tbingen, Heungsoo Shin, PhD, Hanyang University; and John A. Jansen, DDS, PhD, Radboud University, and Xiumei Wang, PhD, Tsinghua University respectively. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on the Tissue Engineering website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industrys most widely read publication worldwide. A complete list of the firms 90 journals, books, and newsmagazines is available on the e Mary Ann Liebert, Inc., publishers website.

More here:
Co-delivery of IL-10 and NT-3 to Enhance Spinal Cord Injury Repair - Mirage News

About a month ago, Medical News Today started a series aiming to bring together the more encouraging research that emerges around COVID-19. We continue with this Special Feature that focuses on an incoming vaccine and other potential treatments for this new coronavirus and the disease it causes.

With this series, we aim to remind our readers that while COVID-19 causes great sorrow and loss around the world, the resulting global emergency has also meant that scientists are working at an unprecedented pace. They are making progress that is easy to overlook among the worrying numbers of new cases and deaths.

Two recent MNT articles COVID-19: 5 reasons to be cautiously hopeful and COVID-19: Physical distancing, drug trials offer hope looked at the latest developments in potential treatments, vaccines, and the outcomes of infection control measures during the pandemic.

We continue our series with this third Special Feature, which continues to monitor progress in the areas mentioned above.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

We focus on a vaccine that some researchers believe may be available by the fall and round up expert opinions on this promising development. We also cover an app-based social tracing system that could help create intelligent physical distancing instead of national lockdowns.

We previously reported that the World Health Organization (WHO) have launched a global megatrial that involves testing four potential treatments for COVID-19. Remdesivir, initially developed to treat Ebola, was one of those four potential treatments.

Now, scientists from the University of Alberta in Edmonton, Canada, say that remdesivir is showing promise in in vitro experiments.

The same team had previously demonstrated that remdesivir effectively combatted another coronavirus, MERS-CoV. It did so by blocking polymerases, which are enzymes that allow the virus to replicate.

Study co-author Prof. Matthias Gtte explains, If you target the polymerase, the virus cannot spread, so its a very logical target for treatment.

He continues to report the results of the teams new experiments: We obtained almost identical results as we reported previously with MERS, so we see that remdesivir is a very potent inhibitor for coronavirus polymerases.

Prof. Gtte goes on to explain, These coronavirus polymerases are sloppy, and they get fooled, so the inhibitor gets incorporated many times, and the virus can no longer replicate.

Still, the author cautions, Weve got to be patient and wait for the results of the randomized clinical trials.

Another hopeful finding comes from researchers from Cornell University in Ithaca, NY. These scientists also started their research efforts by drawing parallels with other coronaviruses, such as SARS-CoV and MERS-CoV.

Namely, they looked at the spike protein that coronaviruses have and zoomed in further on the fusion peptides these are short-chain amino acids that the spike proteins contain.

Whats really interesting about SARS-CoV and MERS-CoV, and this new virus, SARS-CoV-2, is this particular part of the protein, the fusion peptide, is almost exactly the same in those three viruses, explains study co-author Prof. Susan Daniel.

The new study found that calcium ions enable fusion peptides to help coronaviruses penetrate healthy cells through a process called membrane fusion. This offers a potential target for a new antiviral treatment.

The team has already secured funding to start developing an antibody that could stop this process by targeting SARS-CoV-2s fusion peptide.

Blocking the fusion step is significant because the fusion machinery doesnt evolve and change as fast as other parts of the protein do. Its been built to do a particular thing, which is to merge these two membranes together. So if you can develop antiviral strategies to reduce that efficiency, you could have potentially very broadly-acting treatments.

Prof. Susan Daniel

Sarah Gilbert, a professor of vaccinology at Oxford Universitys Jenner Institute in the United Kingdom, and her team may soon be closing in on a vaccine for SARS-CoV-2.

The approach uses a harmless chimpanzee virus to carry the fragment of SARS-CoV-2 that is required for immunity, explains Ian Jones, Professor of virology at the University of Reading, U.K.

Colin Butter, an associate professor of bioveterinary science at the University of Lincoln in the UK, explains: Professor Gilberts team [] have made a recombinant vaccine against the SARS-CoV-2 virus by taking a virus that is entirely harmless to humans, the Chimp Adenovirus designated ChAdOx1, and inserting into it the spike protein gene from the [new] coronavirus.

Prof. Gilbert believes that the vaccine will be available for general use by the fall, which could prevent a potential second wave of the new coronavirus.

That is just about possible if everything goes perfectly, Prof. Gilbert told The Times in an interview. The researchers are set to put the new vaccine into human trials in the next 2 weeks.

The researcher explains that during the pandemic, scientists can fast-track the process through which the vaccine reaches the population by doing many of the necessary steps in parallel.

First, there is the need to manufacture the vaccine for clinical studies under tightly controlled conditions, certified and qualified we need ethical approval and regulatory approval. Then, the clinical trial can start with 500 people in phase I.

This is always in healthy adults aged about 18 to 55, and usually the primary read-out from a phase 1 study is safety, Prof. Gilbert explains. Then we can do phase 2, looking at a wider age range; in this case, we are going to increase the age range, 55 to 70 plus. We are looking at safety in the older age group, [and] we expect to see weaker immune responses.

The researcher explains that she and her team plan to spread their studies across different countries so that they can reduce the time it takes to test the vaccine.

[I]ts vital we go fast before a high proportion [of the population] become infected. But it also means we are going to need to do studies in different countries because the amount of virus transmission is affected by the lockdowns.

The vaccine could get approval under emergency use legislation, meaning that in an emergency situation, if the regulators agree, its possible to use a vaccine earlier than in normal circumstances, Prof. Gilbert adds.

It is worth noting that other experts have expressed concern over Prof. Gilberts estimates.

Prof. David Salisbury, for example, says, [I]t is not just the availability of the first dose that we need to focus on. We need to know by when there will be sufficient doses to protect all of the at-risk population, probably with two doses, and that means industrial-scale manufacturing that governments do not have.

The approach in itself, however, is viable, and the research group benefits from a lot of credibility in the scientific community. The approach has been extensively tested in other situations, so there is indeed a good chance it will work as designed, says Prof. Jones.

The [research] group has a long history of success in this area, adds Dr. Butter. On the basis of this prior experience, it would be reasonable to assume that the vaccine would induce antibody and cellular immune responses, both of which may be important in controlling the virus in an individual.

Any final roll-out will almost certainly need a level of manufacturing the [U.K.] does not readily have, so transfer to and liaison with an external manufacturer may also need to be tackled. But the roadmap is clear, lets hope they get there.

Prof. Ian Jones

Tissue plasminogen activator (tPA) is a drug designed and approved to prevent blood clots in people who have had a stroke, pulmonary embolism, or heart attack.

Now, a new trial to test its benefits for relieving acute respiratory distress syndrome (ARDS) in people with COVID-19 is underway.

TPA acts as an anticoagulant. This means it prevents blood clotting by breaking down fibrin. Fibrin can form plugs in the airways and contributes to small clots in the blood vessels of the lungs.

In patients with COVID-19, these small microfibrin plugs in the air sacs lead to ARDS. As a result, these patients require ventilators to be able to breathe.

Were hearing anecdotally that a subset of patients with COVID-19-induced ARDS are clotting abnormally around their catheters and [intravenous] lines, explains Dr. Michael B. Yaffe, Ph.D., an acute care surgeon at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA.

Dr. Yaffe is also the senior author of the study that proposed repurposing tPA to treat COVID-19 complications.

We suspect these patients with aggressive clotting will show the most benefit from tPA treatment, and this new clinical trial will reveal whether thats the case, says Dr. Yaffe.

The scientists have started to recruit some of the COVID-19 patients admitted to the BIDMC for the trial. The team also hopes to find biomarkers that can help identify patients who are most likely to benefit from the treatment.

If effective and safe for the treatment of ARDS in patients with COVID-19, tPA could save lives by reducing recovery time and freeing up more ventilators for other patients in need.

Christopher D. Barrett, clinical trial investigator

Another finding that may help relieve the pressure on public health systems is a mobile app-based contact tracing system.

The authors of the new project explain that such a system could help reduce the rate at which the virus spreads while also mitigating some harmful effects of a full national lockdown.

Dr. David Bonsall senior researcher at Oxford Universitys Nuffield Department of Medicine, clinician at Oxfords John Radcliffe Hospital both in the UK, and co-lead of the project explains how the system works.

He says, The mobile app concept weve mathematically modeled is simple and doesnt need to track your location. It uses a low energy version of Bluetooth to log a memory of all the app users with whom you have come into close proximity over the last few days.

If you then [contract the virus], these people are alerted instantly and anonymously and advised to go home and self-isolate. If app users decide to share additional data, they could support health services to identify trends and target interventions to reach those most in need.

The findings could pave the way for intelligent [physical] distancing, avoiding the social and economic effects of full lockdowns.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

See more here:
COVID-19: Vaccine may be ready by fall and other reasons for hope - Medical News Today

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development.

Mr. McClungs appointment is the latest in the evolution of Sangamos leadership implemented over the last three years as the Companys technology and research programs have advanced into a diversified pipeline of therapeutic product candidates in various stages of clinical development. During this period, Sangamo has also appointed executive vice presidents overseeing R&D, manufacturing, legal and finance.

Im excited to welcome Mark to Sangamo. With our first product candidate entering Phase 3 and our broad pipeline of proprietary and partnered programs advancing in development, we are increasingly focused on late stage development and commercialization strategies for genomic medicines. Mark has extensive experience leading commercial organizations in therapeutic areas where innovative products have disrupted standards of care, said Sandy Macrae, Sangamos CEO.

From 2015 through 2019, Mr. McClung was Vice President and General Manager of Global Oncology Commercial at Amgen, which he joined from Onyx Pharmaceuticals where he had served as Chief Commercial Officer. For two decades prior, Mr. McClung held roles of increasing responsibility at GlaxoSmithKline in marketing and sales, commercial operations, and general management in the United States and Europe, including as Vice President and Head of Global Commercial for GSK Oncology from 2009 2013.

Over the next decade, genomic medicines have the potential to transform the practice of health care across therapeutic areas from rare monogenic diseases to immunology and oncology, and even to highly prevalent neurological disorders such as Alzheimers disease and Parkinsons disease, Mr. McClung commented. With its deep scientific expertise, diverse technology platforms, broad pipeline and significant collaborations, Sangamo is well positioned for this new era, and Im thrilled to join the Company at this time.

Stephane Boissel, Executive Vice President of Corporate Strategy, will leave Sangamo at the end of July and eventually return to an entrepreneurial project. Mr. Boissel joined Sangamo in 2018 following the acquisition of TxCell (now Sangamo France), where he had served as CEO.

Stephanes impactful contributions to Sangamo will endure for many years. He has driven several remarkable deals to fruition, including most recently our transaction with Biogen, which is among the largest preclinical collaboration deals ever, Macrae said. It has been an enormous pleasure working with Stephane these last two years, and we wish him every success in the future.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize immunology and oncology therapies, therapies to treat rare monogenic diseases, neurological diseases and other diseases and other therapies and the timing and availability of such therapies, the potential for Sangamo to receive upfront licensing fees and earn milestone payments and royalties under the Biogen and other collaborations and the timing of such fees, payments and royalties, Sangamos product pipeline, technology platforms and scientific expertise, Sangamos financial resources and expectations and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the research and development process; the regulatory approval process for product candidates; the commercialization of approved products; the potential for technological developments that obviate Sangamo's technologies; the potential for Biogen to breach or terminate the collaboration agreement; and the potential for Sangamo to fail to realize its expected benefits of the Biogen and other collaborations. There can be no assurance that Sangamo will earn any upfront licensing fees or milestone or royalty payments under the Biogen or other collaborations or obtain regulatory approvals for product candidates arising from these collaborations. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200417005086/en/

More:
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer - BioSpace

Money is on the way. At least that's the case if you're among the 80 million Americans who qualify for the coronavirus stimulus checks funded by theCoronavirus Aid, Relief, and. Economic Security (CARES) Act signed into law last month.

For too many, the $1,200 payment will be needed simply to make ends meet. Others, though, will have extra money to spend or to invest. If you're in the latter group, investing your stimulus check makes a lot of sense with the stock market still down by a double-digit percentage from the highs set earlier this year.

But which stocks are great picks that could generate explosive growth over the next several years? Here are three stocks to buy to get a big bang for the buck with your coronavirus stimulus check.

Image source: Getty Images.

Shares of MongoDB (NASDAQ:MDB) sank as much as 45% in mid-March before bouncing back nicely. But the stock is still down well below its previous highs. I think buying MongoDB now will enable patient investors to reap tremendous gains over the long run.

The last two letters of MongoDB's name reveal the company's focus on the database market. But MongoDB's database is different from the big players in the industry in a couple of important ways. First, it was designed from the ground up for the unstructured data that's being generated in massive quantities today, like images and videos. Second, MongoDB created its database to be run from anywhere, including the cloud.

I really like the first part of the company's name, though, because it hints at the size of the opportunity that lies ahead. "Mongo" is short for "humongous." And MongoDB definitely has a humongous opportunity. The global database market is expected to grow to $97 billion by 2023 from $71 billion this year. MongoDB currently captures less than 1% of the market, but it's growing faster than its much larger rivals.

A major key to MongoDB's success is its Atlas cloud-based database-as-a-service. The company reported 80% year-over-year sales growth for Atlas in Q2, with the fully managed cloud database now generating 41% of MongoDB's total revenue. I expect Atlas will continue to fuel MongoDB's tremendous growth and help the company snag a lot more of the expanding global database market over the next five years.

Fastly's(NYSE:FSLY) name also hints at what the company does -- delivering web content to users faster than other technologies. The company's platform moves data and applications closer to users at the edge of the network, the point right before an organization loses control of its data.

You could also say that the company's name describes its own growth. Fastly reported 44% year-over-year revenue growth in the fourth quarter of 2019. Its number of enterprise customers in Q4 increased to 288 with an average spend of $607,000, up from 274 enterprise customers in Q3 with an average spend of $575,000.

The edge cloud platform and content delivery network technology offered by Fastly will almost certainly enjoy even greater demand in the future with the rise of 5G wireless networks. While major cloud services providers including Amazon.comand Microsoftwill compete against Fastly, the growth in the overall market should be enough for multiple winners.

Fastly stock now trades at a double-digit percentage discount from earlier this year. It's still expensive based on conventional valuation metrics but with its strong growth prospects, I think this tech stock will be a winner over the long term.

In keeping with our theme of what's in a name,Editas Medicine (NASDAQ:EDIT)also picked its corporate name to indicate the business it's in. The company is a leader in the development of gene-editing therapies that use CRISPR, a method of gene editing that has been hailed as the biotech discovery of the century.

Unlike MongoDB and Fastly, Editas can't boast of impressive revenue growth yet. That's because the company is still several years away from the possibility of winning regulatory approval for its first drug. But Editas is making progress toward the goal of launching its first product.

In March, Editas and its partner, Allergan, dosed the first patient in the world's first clinical study in humans evaluating an in vivo (inside the body) CRISPR gene-editing therapy. This study will assess the safety, efficacy, and tolerability of a CRISPR therapy targeting Leber congenital amaurosis type 10 (LCA10), the most common cause of genetic childhood blindness.

Editas is also working on advancing a promising CRISPR therapy for treating rare genetic disorder sickle cell disease and hopes to file for approval by the end of 2020 to begin a clinical study. It's also developing an experimental CRISPR therapy for treating solid tumors. The biotech stock is the riskiest of these three, but if Editas is successful with its gene-editing programs it could potentially be the biggest winner of all.

Read more from the original source:
3 Stocks to Buy to Get a Big Bang for the Buck With Your Coronavirus Stimulus Check - The Motley Fool

Newswise Pancreatic cancer is expected to become the second-deadliest cancer in the United States by 2030, driven in part by rising obesity rates. A new study led by Yale Cancer Center (YCC) researchers has demonstrated in mice that hormones released from the pancreas itself can advance pancreatic cancer and that weight loss can stop this process in its early stages. The research was published today in the journal Cell.

These discoveries raise the hope of finding new ways to prevent both the growth and the spread of pancreatic cancer, said Mandar Muzumdar, M.D., assistant professor of genetics at Yale School of Medicine, a member of the Yale Cancer Biology Institute, and senior author of the paper.

Muzumdar and his collaborators, including a team from the Massachusetts Institute of Technology (MIT), began the project with a mouse model that was genetically modified to develop pre-cancerous pancreatic lesions with a mutation in the KRAS gene, which is mutated in most human pancreatic cancers. The mice were also genetically engineered both to become obese and to rapidly lose weight when scientists administered an additional form of genetic manipulation or limited their food intake.

Unlike mice of normal weight engineered with the KRAS mutation, obese mice with this mutation rapidly developed advanced pancreatic cancer. And unlike most humans diagnosed with the disease, tumors in the model mice did not present additional genetic mutations that would further enable tumor progression. Just by making them obese, we could essentially simulate the effect of an additional mutation, Muzumdar said. That suggested that there is a huge effect of obesity on cancer development in mice.

Next, he and his colleagues studied whether weight loss could slow the development of cancer in the mice who had developed pre-cancerous lesions. The results were dramatic. We found that if we made the mice lose weight prior to advanced cancer development, we could essentially block the progression to advanced cancer almost as if they were never obese, Muzumdar said. If we made the mice lose weight after advanced cancers had developed, the mice still succumbed to the disease within the same timeframe.

The finding suggested the possibility of intercepting tumor formation or progression by weight loss, or eventually using novel drugs that target the underlying biological pathways. Muzumdar noted that the result matches up well with clinical studies of people who are given weight-reducing bariatric surgery, which appears to lower the risk of developing pancreatic cancer.

To determine the cause of the tumors in these mice, the team looked at the genes being expressed in clusters of hormone-producing cells called islets in their pancreases. One type of pancreatic islet cell known as a beta cell normally produces insulin. In these mice, however, some beta cells were churning out a hormone called cholecystokinin (Cck), normally generated in the intestine to aid digestion. These beta cells also seemed to secrete less insulin. This finding interested Muzumdar and his team because they knew that the Cck hormone acts on the digestive enzyme-secreting cells where the predominant type of pancreatic cancer emerges.

They also discovered that Cck expression in the islets dropped when the obese mice lost weight. Additionally, other mouse models that were engineered with the KRAS mutation and forced to express Cck in beta cells, but were not obese, were more likely to form pancreatic tumors than mice engineered with the KRAS mutation alone.

Muzumdars lab is now studying why beta cells switch from making insulin to Cck. Another key puzzle is how Cck can boost tumor formation and progression. Our hope is that the underlying pathways and mechanisms were identifying in obesity also may apply to those who develop pancreatic cancer in the absence of obesity, he added.

Lead authors on the paper include Jaffarguriqbal Singh and Lauren Lawres from Yale and Katherine Minjee Chung and Kimberly Judith Dorans from MITs Koch Institute of Integrative Cancer Research. Yales Cathy Garcia, Daniel Burkhardt, Rebecca Cardone, Xiaojian Zhao, Richard Kibbey, Smita Krishnaswamy and Charles Fuchs contributed to the study, as did Rebecca Robbins, Arjun Bhutkar and Tyler Jacks from MIT. Other contributors included Ana Babic, Sara Vayrynen, Andressa Dias Costa and Brian Wolpin from Dana-Farber Cancer Institute; Jonathan Nowak from Brigham and Womens Hospital; Daniel Chang of Stanford Cancer Institute; Richard Dunne and Aram Hezel of the University of Rochester Medical Center; Albert Koong of the University of Texas MD Anderson Cancer Center; Joshua Wilhelm and Melena Bellin of the University of Minnesota Medical Center; and Vibe Nylander, Anna Gloyn and Mark McCarthy of the University of Oxford.

Funding for the study was provided by the Lustgarten Foundation, the National Institutes of Health, and YCC.

About Yale Cancer Center and Smilow Cancer HospitalYale Cancer Center (YCC) is one of only 51 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Smilow Cancer Hospital is accredited by the Commission on Cancer, a Quality program of the American College of Surgeons. Comprehensive cancer centers play a vital role in the advancement of the NCIs goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

###

Go here to see the original:
Study points to obesity as driver of pancreatic cancer - Newswise

The pharmaceutical industrys response to the novel coronavirus may not rescue its ailing reputation. But it will, apparently, be televised and the footage could nudge the publics perception of how the drug business works.

That, at least, is the thinking behind a 30-minute weekly show from the multinational drug company Johnson & Johnson being launched Tuesday. The eight-episode series, which will be broadcast live online, will focus on the companys efforts to find a vaccine for the virus that causes Covid-19. J&J hired journalist Lisa Ling, of CNNs This Is Life, to host the program.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

See original here:
Johnson & Johnson tries to turn vaccine development into reality TV - STAT